免疫靶向联合局部治疗不可切除肝细胞癌的临床疗效  

Clinical efficacy of immunotherapy plus targeted therapy combined with local treatment for unresectable hepatocellular carcinoma

作　　者：张维晨[1] 余松峰[1] 周坦洋[2] 郑怡[3] 史海燕 沈樑 程龙宇[1] 吴东炎 俞军[1] Zhang Weichen;Yu Songfeng;Zhou Tanyang;Zheng Yi;Shi Haiyan;Shen Liang;Cheng Longyu;Wu Dongyan;Yu Jun(Department of Hepatobiliary and Pancreatic Surgery,the First Affiliated Hospital,Zhejiang University School of Medicine,Hangzhou 310003,China)

机构地区：[1]浙江大学医学院附属第一医院肝胆胰外科,杭州310003 [2]浙江大学医学院附属第一医院介入科,杭州310003 [3]浙江大学医学院附属第一医院肿瘤科,杭州310003 [4]浙江大学医学院附属第一医院肝病内科,杭州310003

出　　处：《中华消化外科杂志》2022年第S01期25-28,共4页Chinese Journal of Digestive Surgery

摘　　要：免疫联合靶向治疗能使不可切除肝癌患者生存获益。阿替利珠单克隆抗体联合贝伐珠单克隆抗体在晚期肝癌患者中取得令人瞩目的疗效,但不可切除肝癌患者的转化治疗效果仍需更多证据支持。笔者报道1例乙型病毒性肝炎肝硬化合并肝细胞癌不可切除患者行免疫靶向联合局部治疗的临床疗效。其研究结果显示:患者术后9个月均未发现肿瘤复发,疗效良好。Immunotherapy combined with targeted therapy can benefit the survival of patients with unresectable hepatocellular carcinoma.Atezolizumab combined with bevacizumab has achieved remarkable efficacy in patients with advanced hepatocellular carcinoma,but the efficacy of conversion therapy in patients with unresectable hepatocellular carcinoma still needs more evidences.The authors report the clinical efficacy of a case of unresectable hepatocellular carcinoma with hepatitis B virus related liver cirrhosis who was treated with immunotherapy plus targeted therapy combined with local treatment.Results show a good effect in patient without tumor recurrence after postoperative 9 months.

关 键 词：肝肿瘤 局部治疗 免疫治疗 靶向治疗 转化治疗 

分 类 号：R735.7[医药卫生—肿瘤]